Trial
NCT00733122
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
Phase IIIWITHDRAWNREGULATORYConfidence: MEDIUM
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
HPV Infections
Intervention
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Why stopped
Following the direction of the local (India) health authority, data specified in the protocol were not collected and study was cancelled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-03